pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Lyfgenia
drug · gene
save

lovotibeglogene autotemcel

Phase 3updated 3mo ago
by Genetix Biotherapeutics Inc🔗 ChEMBL
Phase 3
community read0 votes

Gene drug with a maximum clinical stage of Approval, with an approval for sickle cell disease.

indications

indications
Sickle Cell Disease

targets

Hemoglobin subunit beta

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand
Lyfgenia
trade names
Lyfgenia
generic
lovotibeglogene autotemcel
MOA
Hemoglobin beta chain exogenous gene
indication
Sickle Cell Disease
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?